MRKR News and Press, Marker Therapeutics Inc. From 11/10/21

Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results Enrollment of first 20 patients of the Company's Phase 2 AML trial anticipated in Q4 2021 Topline readout of Group 2 active disease anticipated in Q1 2022 Company to host year-end conference c...

MRKR has been trading downwards and sideways for months now. I was asked to see if I can figure out why. It appears that there's a catalyst desert that's been taking its toll on the stock's performance. For further details see: Marker Therapeutics: Passing Through A Cata...

Marker Therapeutics to Present at Three Upcoming September Investor Conferences PR Newswire HOUSTON , Sept. 7, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-g...

Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas PR Newswire HOUSTON , Aug. 19, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing...

Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results Marker continues to enroll patients and activate clinical sites in Phase 2 AML trial following completion of safety lead-in Company's new in-house cGMP manufacturing facility in Houston is fully ...

Marker Therapeutics (MRKR) announces that the company's new cGMP manufacturing facility in Houston, TX is fully operational. The facility will manufacture Marker's MultiTAA-specific T cell products for the company's Phase 2 acute myeloid leukemia ((AML)) trial as well as future...

Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility Facility is now available to manufacture study drug, MT-401, for Marker's Phase 2 AML trial PR Newswire HOUSTON , July 28, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasda...

Marker Therapeutics (MRKR) announces completion of the six-patient safety lead-in portion of the company's Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product candidate, for the treatment of post-transplant acute myeloid leukemia ((AML)).The multicenter mid-stage study is evalu...

Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML Company continues to enroll patients in main portion of the Phase 2 trial with topline data from active disease group expected in Q1 2022 PR Newswire HOUSTON ...

Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference PR Newswire HOUSTON , June 16, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the developmen...